Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23253945 | 0.92 | MAPT (0.45) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20183704 | 0.91 | MAPT (0.48) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL20183776 | 0.88 | KMT2A (0.61) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20195131 | 0.87 | ALDH1A1 (0.44) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL21549485 | 0.83 | MAPT (0.47) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL21473965 | 0.81 | MAPT (0.51) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL20183733 | 0.78 | HIF1A (0.41) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL20195221 | 0.77 | MEN1 (0.47) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20354153 | 0.76 | KMT2A (0.46) | MAPTMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL20183547 | 0.71 | GAA (0.47) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137505-B | Nitrogen-containing heterocyclic compound | 富士胶片株式会社 | 2021-07-06 | — | — | CN | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| WO-2018124180-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | 富士フイルム株式会社 | 2018-07-05 | — | — | WO | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | ENPP2 2365/4885MAPT 3928/4885MEN1 1349/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | ENPP2 972/4885MAPT 4325/4885MEN1 524/4885 |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | BRD4, BRD1, BRD3 | ENPP2 2365/4885MAPT 3928/4885MEN1 1349/4885 |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CXCL10, CCL5, CXCR3 | ENPP2 972/4885MAPT 4325/4885MEN1 524/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | ENPP2 567/4885MAPT 4406/4885MEN1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.